FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Slides:

Advertisements

Similar presentations

Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Information (CMI) National Association of Chain Drug Stores.

Advertisements

ClimDev-Africa Program & African Climate Policy Center (ACPC)

CDCs 21 Goals. CDC Strategic Imperatives 1. Health impact focus: Align CDCs people, strategies, goals, investments & performance to maximize our impact.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

5th Annual PBM Pharmacy Informatics Conference

Conference for FOOD PROTECTION Promoting Food Safety Through Collaboration.

FDA Advisory Committees: A Unique Element of our Decision-Making Process Murray M. Lumpkin, M.D. Acting Deputy Commissioner International and Special Programs.

Audit Committee in Albania Legal framework Law 9226 /2006 “On banks in Republic of Albania” Law 9901/2008 “On entrepreneurs and commercial companies” Corporate.

FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.

CFSAN’s Peer Review for Risk Assessments Robert L. Buchanan, Sherri Dennis, and Marianne Miliotis.

Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.

Process for Policy Development and Mechanism for Policy Concerns.

Membership and Personnel Requirements for VCA Programs (Resolution 27) Vascularized Composite Allograft (VCA)Transplantation Committee Sue V. McDiarmid,

Introduction to Regulation

April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.

CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Committee Planning and Budgeting Tool: Outlining the Roles and Responsibilities of Selected Committee Support Personnel A Presentation to Committee 8 July2014.

1 Drug Safety Oversight Board Update DIA Annual Meeting Philadelphia, PA June 21 st, 2006 Susan K. Cummins, MD, MPH Executive Director Drug Safety Oversight.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office.

Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Dual Use Research of Concern Boston University and Boston Medical Center.

Raising and acting on concerns about patient safety General Medical Council

Planned Emergency Research Exception from Informed Consent Requirements September 2007.

Proposal to Clarify Data Submission Reporting and Documentation Requirements (Resolution 22) Membership & Professional Standards Committee (MPSC) Jonathan.

The work of the Research Ethics Committee Dr Carol Chu.

New Drug Safety Initiatives & the Drug Safety Oversight Board Drug Safety and Risk Management Advisory Committee, Gaithersburg, MD February 10 th, 2006.

Drug Transfer Into Breast Milk and Interpretation of Data Lawrence J. Lesko Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation.

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

1 Best Practices in Stakeholder Involvement Paul J. Seligman, M.D., M.P.H. Associate Director, Safety Policy & Communication Center for Drug Evaluation.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

Corporate Governance.  According to King III, the board should: ◦ be responsible for the strategic direction and control of the company; ◦ set the values.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Managing Conflicts of Interest at the IRB and Institutional Level: INSTITUTIONAL CONFLICTS OF INTEREST Claudia R. Adkison, J.D., Ph.D. Executive Associate.

Australian Health Ethics Committee Professor Colin Thomson address to International Dialogue on Ethics European Commission Bureau of European Policy Advisers.

PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.

Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

S 1 Annual Meeting 2013 Management and reporting (WP6) Chiara Bearzotti NACLIM project manager.

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Local Pension Boards for the Firefighters’ Pension Schemes: A discussion document April 2014.

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.

Paul Kelly Facility Research Compliance Officer for the Ralph H. Johnson VA Medical Center.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

1 RISK MANAGEMENT PUBLIC WORKSHOPS APRIL 9-11, 2003 NTSB BOARD AND CONFERENCE CENTER WASHINGTON, DC.

Risk Management, Risk Communication, and Drug Safety: The U.S. Experience Geoffrey Levitt Chief Regulatory Counsel Wyeth August 23, 2007.

1 CONSUMERS IN COCHRANE PROVIDENCE, RI April 2004 LIZ WHAMOND.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

Fostering Antimicrobial Stewardship in Animals: Overview of FDA Activities William Flynn, DVM, MS Deputy Director for Science Policy Center for Veterinary.

H1N1 Vaccine Safety Subgroup: Draft Recommendations to NVAC NVAC Teleconference July 27, 2009 Daniel Salmon Vaccine Safety Specialist National Vaccine.

The International Professional Practices Framework

1 1 Influencing Evaluation Policy and Practice: A Progress Report from AEA’s Evaluation Policy Task Force Patrick Grasso Chair, AEA Evaluation Policy Task.

Reporting Approaches and Best Practices Jennifer Benjamin NCQA

Outline: OCS Overview: Organizational Structure USDA Coordination

Professional Organizations

Commission strategy to

Presentation transcript:

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research Food and Drug Administration

April 15, 2005FDA SCIENCE BOARD2 Drug Safety – Change at FDA Outline Dr. Crawford’s November announcement Secretary Leavitt’s February announcement What’s coming

April 15, 2005FDA SCIENCE BOARD3 Drug Safety – Specific Actions Acting Commissioner Crawford’s 5-Point Plan Announced in November Sponsor an Institute of Medicine (IOM) Study of the Drug Safety System Implement a Program for Adjudicating Differences of Professional Opinion Appoint Director, Office of Drug Safety Conduct Drug Safety/Risk Management Consultations Publish Risk Management Guidances

April 15, 2005FDA SCIENCE BOARD4 February Drug Safety Announcement – FDA Actions in 4 categories Overall goals: promote a culture of openness and enhanced oversight within the FDA Specific areas of change: 1. More outside expert consultations 2. Improve drug safety management practices 3. Change how we communicate about emerging drug risks to improve transparency 4. Continue our work to improve scientific methods of AE signal detection

April 15, 2005FDA SCIENCE BOARD5 Drug Safety Initiative The initiative will: Give patients, healthcare professionals and other consumers quick and easy access to the most up-to-date and accurate information on medicines. Make FDA’s drug review, approval, and monitoring programs as transparent as possible.

April 15, 2005FDA SCIENCE BOARD6 Drug Safety Initiative New drug safety information outlets Proposed Drug Watch Program Patient Information Sheets Healthcare Professional Sheets Drug Safety Oversight Board

April 15, 2005FDA SCIENCE BOARD7 Drug Safety Oversight Board Will provide independent oversight and advice to the CDER Center Director on management of: Important drug safety issues and policies. Dissemination of certain safety information through FDA’s website to healthcare professionals and patients.

April 15, 2005FDA SCIENCE BOARD8 Drug Safety Oversight Board Membership Chair – Deputy Director, CDER Executive Director – Dr. Susan Cummins Membership - representatives from relevant CDER offices, CBER, CDRH, NIH, VA. Consumer or patient representatives and advisory committee members as consultants. CDER is will make operating procedures available explaining the Board in more detail very soon.

April 15, 2005FDA SCIENCE BOARD9 Drug Safety Information – new steps Proposed “Drug Watch” web page List of drugs being watched Patient information sheets Physician information sheets

April 15, 2005FDA SCIENCE BOARD13 Summary FDA responsive to concerns about drug safety decision making and communication While comprehensive review underway, we will implement important changes to improve public knowledge, internal management and outside involvement Changes will not be free of controversy and may raise important new issues for resolution